drugset
drugset / Trial / NCT06028425

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

NCT06028425 ↗

Phase 1 Completed 42 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to measure how much of LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered in fasting and fed states in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783. Participation could last up to 63 days including screening period.

Timeline

Start
2023-09-01
Primary completion
2023-12-23
Completion
2023-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject LOXO-783 Unknown — Oral

Indications

No indication recorded.